CN102961331A - Iodine-chitosan solution formula and preparation method thereof - Google Patents
Iodine-chitosan solution formula and preparation method thereof Download PDFInfo
- Publication number
- CN102961331A CN102961331A CN2012105559060A CN201210555906A CN102961331A CN 102961331 A CN102961331 A CN 102961331A CN 2012105559060 A CN2012105559060 A CN 2012105559060A CN 201210555906 A CN201210555906 A CN 201210555906A CN 102961331 A CN102961331 A CN 102961331A
- Authority
- CN
- China
- Prior art keywords
- iodine
- chitosan
- purified water
- plays
- glycerol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000009472 formulation Methods 0.000 title description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 45
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000008213 purified water Substances 0.000 claims abstract description 16
- 229920001213 Polysorbate 20 Polymers 0.000 claims abstract description 15
- 229960000583 acetic acid Drugs 0.000 claims abstract description 15
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 15
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 15
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract description 15
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims abstract description 15
- 229940093930 potassium iodate Drugs 0.000 claims abstract description 15
- 235000006666 potassium iodate Nutrition 0.000 claims abstract description 15
- 239000001230 potassium iodate Substances 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 43
- 239000011630 iodine Substances 0.000 claims description 43
- 229910052740 iodine Inorganic materials 0.000 claims description 43
- 238000003756 stirring Methods 0.000 claims description 9
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000010668 complexation reaction Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 19
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 11
- 230000001954 sterilising effect Effects 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 3
- 238000005063 solubilization Methods 0.000 abstract description 3
- 230000007928 solubilization Effects 0.000 abstract description 3
- 235000011187 glycerol Nutrition 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 239000003381 stabilizer Substances 0.000 abstract description 2
- 229940068977 polysorbate 20 Drugs 0.000 abstract 3
- 229960005150 glycerol Drugs 0.000 abstract 2
- 208000025157 Oral disease Diseases 0.000 abstract 1
- 201000008100 Vaginitis Diseases 0.000 abstract 1
- 229940045110 chitosan Drugs 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 208000030194 mouth disease Diseases 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- 210000002421 cell wall Anatomy 0.000 description 5
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical class II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- -1 plays solubilization Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an iodine-chitosan solution formula and a preparation method thereof. The raw materials of the iodine-chitosan solution include iodine-chitosan, glacial acetic acid, polysorbate-20, glycerol, potassium iodate and purified water. The preparation method comprises the following steps that: (1) the materials are weighed; (2) the glacial acetic acid, polysorbate-20, glycerol and purified water are added into the iodine-chitosan and uniformly mixed to totally dissolve; (3) the potassium iodate is dissolved by the purified water and then added into the materials and uniformly mixed; (4) the purified water is added inside the materials to reach 100 percent and the materials are uniformly mixed; and (5) the mixture is filtered, filled, packaged to obtain the iodine-chitosan solution. In the iodine-chitosan solution, the iodine-chitosan plays the role of disinfection and sterilization, the glacial acetic acid plays the role of pH value adjustment and synergetic solubilization, the polysorbate-20 plays the role of solubilization, the glycerol plays the role of blending and moisture retention, the potassium iodate plays the role of a stabilizer, and the iodine-chitosan plays the role of disinfection; and the iodine-chitosan solution can be used for skin disinfection of operation sites or injection sites and auxiliary treatment of small cuts, and also can be used for washing treatment of vagina inflammation and treatment and disinfection of oral diseases.
Description
Technical field
The present invention relates to medical dressing, particularly contain the dressing of polysaccharide derivates, specifically, relate to chitosan iodine solution.
Background technology
Iodine is used for the history in existing 150 years of body sterilization, but because the dissolubility of iodine in water is very little, only has 1.315 * 10 under 25 ℃
-3Mol/L can not be made into aqueous formulation and use; At room temperature easily distillation, content is unstable; The shortcomings such as zest are arranged and limited its extensive use mucocutaneous.At present, widely used povidone iodine class disinfectant is as carrier mostly take organic polymer or surfactant, by network structure or the micelle that forms between carrier molecule, with the conformational effect in electronics and space with iodine " constraint " in wherein, thereby change the free state of iodine in general Operand, make its stability and bactericidal action enhancing, zest and xanthochromia reduction.But original micelle power can be destroyed after dilution for the finished product of this class take surfactant as carrier, makes the stability decreases of active iodine, thereby affect its sterilization effect.At present, most widely used povidone iodine class disinfectant is the povidone iodine complex in China, is recorded in version " two ones of Chinese pharmacopoeia in 2010.But polyvidone is less to the dissolubility of iodine, and molecular weight large (can up to 70000), and difficulty is biodegradable, and life-time service can produce harmful effect to environment.In addition, itself there is no bactericidal action polyvidone, just forms micelle as a kind of surface activity carrier, improves the stability of iodine molecule.
Chitosan (chitosan) is the unique positively charged side chain polysaccharide of occurring in nature, has antibioticly, and antitumor strengthens the functions such as immunity, has good biocompatibility, and nonirritant, has no side effect, because 2-NH
2Existence, chitosan has certain bacteria resistance function, but bacteriostasis property is limited, and is subject to the impact of the conditions such as chitosan molecule amount, deacetylation.Behind grafting quaternary ammonium salt on the chitosan molecule chain, can significantly improve its bacteriostasis property.Chitosan gathers at the cell wall place easily as a kind of natural polycation, stops nutrient substance to enter cell by cell wall, makes cell failure dead; Low molecular chitosan then can hinder DNA to the transcribing of RNA, and affects the growth and breeding of antibacterial, thereby produces antibacterial action.Chitosan also has bactericidal action, and under acid condition, the amino in the chitosan molecule becomes NH with positive charge
3+Absorption is with the antibacterial of negative charge, make the negative charge skewness on bacteria cell wall and the cell membrane, synthesizing of interference cell wall, break Cell wall synthesis and dissolution equilibrium under naturalness, make cell wall trend towards dissolving, cell membrane is not because bearing the osmotic pressure deformation fracture, content such as water, the protein etc. of cell ooze out, and bacterolysis occur and death.
Chitosan is a kind of macromolecular compound of biological property excellence, and behind the absorption iodine, the heat stability of iodine improves greatly, and is the same with other povidone iodine, and chitosan iodine can discharge elemental iodine, thereby has strong sterilization.This finished product is nontoxic, good stability, nonirritant.Bibliographical information there be the sterilization effect of chitosan iodine (see " laboratory observation of chitosan iodine liquid bactericidal effect ", be stated from Hengyang Medical College's journal (medicine) 05 phase in 2000); Its used chitosan is water-soluble chitosan.
In Chinese patent database, the patent application that relates to the chitosan iodine preparation is few, and CN1115254 number " preparation of chitosan iodine wound and burns dressing ", CN1587281 number " preparation method of chitosan quaternary ammonium salt ", CN101816678A number " a kind of broad-spectrum contact type hemostatic medical fungicide and preparation method thereof " are only arranged.Therefore people are also exploring more convenient use, more effective chitosan iodine preparation.
Summary of the invention
The purpose of this invention is to provide a kind of good stability, the chitosan iodine solution formula that bactericidal effect is good makes it to be human health service.
Another purpose of the present invention provides the preparation method of above-mentioned chitosan iodine solution, enables to realize clinical practical application.
The chitosan iodine solution that the inventor provides, take chitosan iodine as main active, its raw materials quality prescription is as follows:
Chitosan iodine 0.2%～5.0%
Glacial acetic acid 0.1%～5.0%
Tween-20 0.6%～30%
Glycerol 0.2%～10%
Potassium iodate 0.005%～0.25%
Purified water adds to 100%.
The raw material preferred mass prescription of chitosan iodine solution is as follows:
Chitosan iodine 2%
Glacial acetic acid 0.5%
Tween-20 3%
Glycerol 1%
Potassium iodate 0.025%
Purified water adds to 100%.
Above-mentioned chitosan iodine is to be the finished product that raw material and iodine complexation form with water-insoluble chitosan.
Above-mentioned glacial acetic acid, Tween-20, glycerol, potassium iodate, purified water all meet the requirement of the Pharmacopoeia of the People's Republic of China.
The preparation method of the chitosan iodine solution that the inventor provides may further comprise the steps:
1. according to the various materials of raw materials quality prescription weighing, for subsequent use;
2. in chitosan iodine, add glacial acetic acid, Tween-20, glycerol, partial purification water, stir, make fully dissolving, for subsequent use;
3. the purified water that takes a morsel dissolving potassium iodate, and join in the material for subsequent use and mix, stir;
4. add to 100% with remaining purified water, stir, get product.
In the preparation chitosan iodine solution provided by the invention, chitosan iodine plays sterilizing, promotes healing, glacial acetic acid is used for regulating pH value and playing collaborative solubilizing effect, Tween-20 mainly plays solubilization, glycerol plays blending and moisture-keeping function, potassium iodate plays stabilizer function, and purified water is diluent.This chitosan iodine solution is to gram positive bacterias such as staphylococcus aureus, staphylococcus epidermidis, beta hemolytic streptococcus, bacillus subtilises, to gram negative bacterias such as escherichia coli, Pseudomonas aeruginosa, gonococcuss, to funguses such as Candida albicans, epidermophyton, trichophytons, to acid-fast bacillis such as tubercule bacillus; Infusorian etc. all there is killing action; Have simultaneously hemostasis, promote the effect that wound tissue heals.This chitosan iodine solution is through In vitro Bactericidal Experiments, and effect is better than betagen solution, through animal test results proof nonirritant, sensitization; Be applicable to sterilization and the auxiliary treatment of operation, the processing of injection site skin degerming and small size wound (as: hurting, dampen, put on the skin wound, burn, scald, suppurative wound); Also be applicable to the Arthrocentesis of bacillary, mycotic, trichomonal vaginitis disease; Also be applicable to the sterilization of gargle treatment and the oral mucosa of oral ulcer, stomatitis, periodontitis, gingivitis.
The specific embodiment
Describe the specific embodiment of the present invention in detail by the following example:
EXAMPLE lAccording to following prescription weighing: chitosan iodine 0.2g, glacial acetic acid 0.1g, Tween-20 0.6g, glycerol 0.2g, potassium iodate 0.005g, distilled water adds to 100g.In chitosan iodine, add glacial acetic acid, Tween-20, glycerol, partial purification water and stir, make fully dissolving, for subsequent use; The purified water that takes a morsel afterwards dissolving potassium iodate, and join in the material for subsequent use and mix, stir; Purified water with remainder adds to 100g, stirs, and namely gets chitosan iodine solution finished product.
Embodiment 2According to following prescription weighing: chitosan iodine 2g, glacial acetic acid 0.5g, Tween-20 3g, glycerol 1g, potassium iodate 0.025g, distilled water adds to 100g.Method for making obtains chitosan iodine solution finished product with embodiment 1.
Embodiment 3According to following prescription weighing: chitosan iodine 5g, glacial acetic acid 5g, Tween-20 30g, glycerol 10g, potassium iodate 0.25g, distilled water adds to 100g.Method for making obtains chitosan iodine solution finished product with embodiment 1.
Claims (4)
1. chitosan iodine solution is characterized in that this solution take chitosan iodine as main active, and its raw materials quality prescription is as follows:
Chitosan iodine 0.2%～5.0%
Glacial acetic acid 0.1%～5.0%
Tween-20 0.6%～30%
Glycerol 0.2%～10%
Potassium iodate 0.005%～0.25%
Purified water adds to 100%.
2. chitosan iodine preparation as claimed in claim 1 is characterized in that the raw materials quality prescription of described chitosan iodine solution is as follows:
Chitosan iodine 2%
Glacial acetic acid 0.5%
Tween-20 3%
Glycerol 1%
Potassium iodate 0.025%
Purified water adds to 100%.
3. such as the described chitosan iodine solution in one of claim 1 or 2, it is characterized in that described chitosan iodine is that water-insoluble chitosan and iodine get through complexation reaction preparation.
4. the method for preparing the described chitosan iodine solution in one of claim 1 or 2, its feature may further comprise the steps:
1. according to the various materials of raw materials quality prescription weighing, for subsequent use;
2. in chitosan iodine, add glacial acetic acid, Tween-20, glycerol, partial purification water, stir, make fully dissolving, for subsequent use;
3. the purified water that takes a morsel dissolving potassium iodate, and join in the material for subsequent use and mix, stir;
4. add to 100% with remaining purified water, stir, get product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105559060A CN102961331A (en) | 2012-12-20 | 2012-12-20 | Iodine-chitosan solution formula and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105559060A CN102961331A (en) | 2012-12-20 | 2012-12-20 | Iodine-chitosan solution formula and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102961331A true CN102961331A (en) | 2013-03-13 |
Family
ID=47791951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105559060A Pending CN102961331A (en) | 2012-12-20 | 2012-12-20 | Iodine-chitosan solution formula and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102961331A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933062A (en) * | 2014-03-12 | 2014-07-23 | 贵州扬生医用器材有限公司 | Polyglycosaminoglycan polypeptide complex iodine composite system solution and preparation method thereof |
| CN110286010A (en) * | 2019-06-06 | 2019-09-27 | 强安医疗器械有限公司 | Liquid sample-specific pretreatment liquid and preparation method thereof in a kind of rectum |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001172186A (en) * | 1999-12-16 | 2001-06-26 | Hironori Oka | Therapeutic agent for anti-periodontal disease and coating tool for therapeutic agent for anti-periodontal disease |
| CN101507731A (en) * | 2008-10-30 | 2009-08-19 | 杨玉民 | Chitosan uterus-neck antibiotic film and preparation method thereof |
| CN102144988A (en) * | 2011-03-16 | 2011-08-10 | 贵州扬生医用器材有限公司 | Chitosan cervix uteri anti-microbial membrane and preparation method thereof |
-
2012
- 2012-12-20 CN CN2012105559060A patent/CN102961331A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001172186A (en) * | 1999-12-16 | 2001-06-26 | Hironori Oka | Therapeutic agent for anti-periodontal disease and coating tool for therapeutic agent for anti-periodontal disease |
| CN101507731A (en) * | 2008-10-30 | 2009-08-19 | 杨玉民 | Chitosan uterus-neck antibiotic film and preparation method thereof |
| CN102144988A (en) * | 2011-03-16 | 2011-08-10 | 贵州扬生医用器材有限公司 | Chitosan cervix uteri anti-microbial membrane and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 王科兵等，: "壳聚糖碘液体外抗真菌活性研究", 《解放军药学学报》 * |
| 苏志立: "S型碘伏的处方与配制", 《海峡药学》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933062A (en) * | 2014-03-12 | 2014-07-23 | 贵州扬生医用器材有限公司 | Polyglycosaminoglycan polypeptide complex iodine composite system solution and preparation method thereof |
| CN103933062B (en) * | 2014-03-12 | 2015-10-28 | 贵州扬生医用器材有限公司 | Poly-aminopolysaccharide polypeptide chelated iodine compound system solution and method for making thereof |
| CN110286010A (en) * | 2019-06-06 | 2019-09-27 | 强安医疗器械有限公司 | Liquid sample-specific pretreatment liquid and preparation method thereof in a kind of rectum |
| CN110286010B (en) * | 2019-06-06 | 2021-09-24 | 强安医疗器械有限公司 | Special pretreatment liquid for rectal fluid sample and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103356738B (en) | Skin disinfection gel and its application | |
| EP2775838B1 (en) | Aqueous antimicrobial composition containing coniferous resin acids | |
| CN105055304A (en) | Leave-on skin care and disinfection gel containing composite sterilization component, and preparation method thereof | |
| CN102550601A (en) | Iodine disinfection liquid and preparation method thereof | |
| CN107496439B (en) | A kind of chitosan derivative-based disinfectant and preparation method thereof | |
| CN101642449A (en) | Skin mucous membrane disinfectants and preparation method thereof | |
| CN106421217A (en) | Benzalkonium chloride solution and preparation method thereof | |
| CN103012237B (en) | Amino-acid dual-chain quaternary-amino carboxylate, preparation method and application in microbicides thereof | |
| CN102525841A (en) | Marine organism bacterium-removal oral care liquid | |
| CN102405935B (en) | Protamine compounded preparation, preparation method and application thereof | |
| CN114652767B (en) | Dairy cow nipple medicated bath agent and preparation method thereof | |
| CN103120642B (en) | Gel used for skin diseases and preparation method thereof | |
| CN111557938A (en) | Disinfectant for quickly damaging viral envelope | |
| CN106474053B (en) | A kind of composite high-molecular colloid surface of a wound thimerosal and its preparation method containing amino acid | |
| CN106727669A (en) | A kind of efficiently gentle skin degerming gel and preparation method thereof | |
| CN103110572B (en) | Gynecological antimicrobial gel recipe and preparation method thereof | |
| CN102961331A (en) | Iodine-chitosan solution formula and preparation method thereof | |
| CN109362797A (en) | Iodine disinfectant and preparation method thereof | |
| CN102670648B (en) | Liquid iodine disinfectant, preparation method and used container thereof | |
| CN118161525A (en) | Copper-containing antibacterial gel and application thereof | |
| CN103784968B (en) | A kind of antibiotic-chitosan covalent complex and its preparation method and application | |
| CN109157505A (en) | Anti-bacteria wet keeping gel and preparation method thereof | |
| CN103110976A (en) | Skin antimicrobial gel recipe and preparation method thereof | |
| CN107582737A (en) | A kind of compound chlorohexidene oral-cavity disinfectant and preparation method thereof | |
| CN103690404B (en) | Baby bath agent containing marine biomaterial and compositions, preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C05 | Deemed withdrawal (patent law before 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130313 |